(AOF) – Cash of 13.7 million euros as of June 30, 2023, close to its level of 15.44 million a year earlier, ensures Valbiotis financial visibility until the fourth quarter of 2024. This biotech specialist in the fight against metabolic and cardiovascular diseases shows a half-year net loss of 1.92 million euros compared to 5.09 million a year ago. Operating income more than tripled, to 5.23 million, in line with the strong increase in turnover, which reached 4.24 million euros compared to 635,000 euros a year earlier.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
